title: MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).
abstract: Despite recent advances in the understanding of the biology of renal cell carcinoma (RCC), successful surgical treatment and implementation of novel‑targeted therapies, the prognosis for RCC patients remains poor. Late presentation, tumor heterogeneity and in particular the lack of molecular biomarkers for early detection, classification and the surveillance of RCC treatments are major obstacles. The increasing knowledge regarding the functional role of microRNAs (miRNAs) in pathophysiological processes may provide an important link to the identification of suitable therapeutic targets and diagnostic/prognostic biomarkers for RCC. The aim of this review was to provide new insight into the function of miRNAs in the pathogenesis of RCC and to emphasize their potential as diagnostic and prognostic markers, as well as therapeutic targets.
authors: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
authors: Ming
authors: M
authors: Li
authors: Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
authors: Ying
authors: Y
authors: Wang
authors: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
authors: Yongsheng
authors: Y
authors: Song
authors: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
authors: Renge
authors: R
authors: Bu
authors: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
authors: Bo
authors: B
authors: Yin
authors: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
authors: Xiang
authors: X
authors: Fei
authors: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
authors: Qizhen
authors: Q
authors: Guo
authors: Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
authors: Bin
authors: B
authors: Wu
mesh_terms: D000263:Adenylate Kinase / Q000235:genetics / Q000502:physiology; D014408:Biomarkers, Tumor; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D043171:Chromosomal Instability; D019175:DNA Methylation; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics / Q000502:physiology; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D035683:MicroRNAs / Q000097:blood / Q000235:genetics* / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000502:physiology; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000097:blood / Q000235:genetics* / Q000627:therapeutic use; D015398:Signal Transduction; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics / Q000502:physiology
chemical_list: D014408:Biomarkers, Tumor; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D035683:MicroRNAs; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D019869:Phosphatidylinositol 3-Kinases; D000263:Adenylate Kinase; C110939:adenylate kinase 1